Sign inJoin Free
DashboardSign out
Free Lesson Preview
Module 1: Lesson 1
Master the systematic approach to AE elicitation using open-ended questioning, body system review, and strategies to overcome participant barriers to reporting.
"Are you having any side effects?"
It is, without exaggeration, one of the most common questions asked at clinical trial visits -- and one of the least effective. The participant hears "side effects" and filters their experience through a narrow lens: did the study drug cause anything? If they attribute their headaches to stress, their joint pain to aging, their insomnia to the news, they answer "no" in good faith. And an adverse event goes unreported.
This is not a minor pedagogical point. The entire pharmacovigilance system -- the signal detection chain we traced in Module 1 -- depends on complete capture of adverse events at the site level. And complete capture depends on how coordinators ask questions. Not whether they ask. How.
I have reviewed hundreds of monitoring visit reports over the years, and the pattern is unmistakable: sites that use open-ended, systematic elicitation techniques consistently identify more adverse events than sites that rely on yes/no checklists or leading questions. Not because their participants are sicker. Because their coordinators are more skilled at drawing out what participants actually experienced.
AE elicitation is a clinical skill. It can be taught, practiced, and refined. This lesson teaches the systematic approach.
Clinical Research Coordinator
Full course · Safety Reporting and Pharmacovigilance for CRCs
Free Lesson Preview
Module 1: Lesson 1
Master the systematic approach to AE elicitation using open-ended questioning, body system review, and strategies to overcome participant barriers to reporting.
"Are you having any side effects?"
It is, without exaggeration, one of the most common questions asked at clinical trial visits -- and one of the least effective. The participant hears "side effects" and filters their experience through a narrow lens: did the study drug cause anything? If they attribute their headaches to stress, their joint pain to aging, their insomnia to the news, they answer "no" in good faith. And an adverse event goes unreported.
This is not a minor pedagogical point. The entire pharmacovigilance system -- the signal detection chain we traced in Module 1 -- depends on complete capture of adverse events at the site level. And complete capture depends on how coordinators ask questions. Not whether they ask. How.
I have reviewed hundreds of monitoring visit reports over the years, and the pattern is unmistakable: sites that use open-ended, systematic elicitation techniques consistently identify more adverse events than sites that rely on yes/no checklists or leading questions. Not because their participants are sicker. Because their coordinators are more skilled at drawing out what participants actually experienced.
AE elicitation is a clinical skill. It can be taught, practiced, and refined. This lesson teaches the systematic approach.
Clinical Research Coordinator
Full course · Safety Reporting and Pharmacovigilance for CRCs
This is just the beginning
The full CRC track covers 8 courses from study start-up to close-out — the skills sponsors actually look for.
Start the CRC trackThis is just the beginning
The full CRC track covers 8 courses from study start-up to close-out — the skills sponsors actually look for.
Start the CRC track